Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | DAO | P14920 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | GPR3 | P46089 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450289 | 1.00 | ALOX5 (1.00) | ALOX5POLBKDM4EPARP1CA12 | |
| Hydrochloric Acid SCHEMBL18152218 | 0.97 | ALOX5 (0.95) | ALOX5POLBKDM4EPARP1CA12 | |
| SCHEMBL29349675 | 0.83 | ALOX5 (0.70) | ALOX5POLBKDM4EPARP1CA12 | |
| SCHEMBL29766 | 0.83 | ALOX5 (0.70) | ALOX5POLBKDM4EPARP1CA12 | |
| SCHEMBL15621628 | 0.82 | ALOX5 (0.68) | ALOX5POLBKDM4EPARP1CA12 | |
| SCHEMBL30218500 | 0.80 | ALOX5 (0.67) | ALOX5POLBKDM4EPARP1CA12 | |
| SCHEMBL31438327 | 0.80 | ALOX5 (0.67) | ALOX5POLBKDM4EPARP1CA12 | |
| Hydrochloric Acid SCHEMBL6170559 | 0.80 | ALOX5 (0.67) | ALOX5POLBKDM4EPARP1CA12 | |
| Charcoal, Activated SCHEMBL31491466 | 0.80 | ALOX5 (0.67) | ALOX5POLBKDM4EPARP1CA12 | |
| SCHEMBL19641884 | 0.80 | ALOX5 (0.67) | ALOX5POLBKDM4EPARP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | claimed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | claimed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | claimed |
| CN-109734666-B | Preparation method for synthesizing indazolinones compound by carbon dioxide promotion and photo-induction without photocatalyst | 湖南大学 | 2023-03-28 | — | — | CN | claimed |
| CN-115160228-A | Method for synthesizing 3-indazolinone compound by photocatalysis | 中国科学院大连化学物理研究所 | 2022-10-11 | — | — | CN | claimed |
| EP-3377483-B9 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-03 | — | — | EP | claimed |
| WO-2019077174-A1 | AMINES DERIVED FROM 2-BENZYL-5-NITROINDAZOLE WITH ANTIPROTOZOAL PROPERTIES AGAINST TRYPANOSOMA, LEISHMANIA AND TRICHOMONAS | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2019-04-25 | — | — | WO | claimed |
| WO-2018144680-A1 | METHODS FOR TREATING CANCER USING HSP90 INHIBITORS | LAM THERAPEUTICS, INC. (US) | 2018-08-09 | — | — | WO | claimed |
| US-20180221376-A1 | Methods for treating cancer using HSP90 inhibitors | ORPHAI THERAPEUTICS INC. | 2018-08-09 | — | — | US | claimed |
| EP-0138362-B1 | PHOTOGRAPHIC MATERIALS CONTAINING CHALCOGENAZOLES, CHALCOGENAZOLINES AND CHALCOGENAZOLINIUM AND CHALCOGENAZOLIUM SALTS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-02-22 | — | — | EP | claimed |
| EP-0284174-A1 | Therapeutic preparations | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-28 | — | — | EP | claimed |
| US-4576905-A | Photographically useful chalcogenazoles, chalcogenazolines, and chalcogenazolinium and chalcogenazolium salts | EASTMAN KODAK COMPANY (US) | 1986-03-18 | — | — | US | claimed |
| US-4575483-A | FACILITATE IMAGE FORMATION | EASTMAN KODAK COMPANY (US) | 1986-03-11 | — | — | US | claimed |
| EP-0034950-B1 | HETEROCYCLIC 4- AND 6-EQUIVALENT PHOTOGRAPHIC COLOUR COUPLERS AND PHOTOGRAPHIC MATERIALS AND DEVELOPER COMPOSITIONS CONTAINING THEM | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-01-08 | — | — | EP | claimed |
| EP-0138362-A2 | Photographic materials containing chalcogenazoles, chalcogenazolines and chalcogenazolinium and chalcogenazolium salts | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-24 | — | — | EP | claimed |
| EP-0136847-A2 | Photographically useful chalcogenazolylidene and chalcogenazolium dyes and methods for their preparation | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-10 | — | — | EP | claimed |
| US-4338393-A | COLOR PHOTOGRAPHY | EASTMAN KODAK COMPANY (US) | 1982-07-06 | — | — | US | claimed |
| EP-0034950-A2 | Heterocyclic 4- and 6-equivalent photographic colour couplers and photographic materials and developer compositions containing them | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1981-09-02 | — | — | EP | claimed |
| US-4012258-A | POLY-FLUORO-ALKYL MAGENTA OR CYAN COUPLER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) | 1977-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221376-A1 | Methods for treating cancer using HSP90 inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | ALOX5 3994/4885POLB 1056/4885KDM4E 2872/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | ALOX5 3181/4885POLB 4192/4885KDM4E 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.